Extracorporeal photopheresis in Sezary syndrome [13]

Lancet

Volumn 350, Issue 9081, 1997, Pages 886-

  Russell Jones, R ^a   Fraser Andrews, E ^a   Spittle, M ^a   Whittaker, S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC ANALYSIS; HEALTH CARE COST; HISTOLOGY; HUMAN; LETTER; LYMPHADENOPATHY; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROGNOSIS; PUVA; SEZARY SYNDROME; T CELL LYMPHOMA; TREATMENT OUTCOME; MULTIMODALITY CANCER THERAPY; NOTE; SKIN TUMOR;

COMBINED MODALITY THERAPY; HUMANS; INTERFERON ALFA-2A; PHOTOPHERESIS; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 0031580686     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62067-3     Document Type: Letter

References (4)

1. E Dippel H Schrag S Goerdt CE Orfanas Extracorporeal photopheresis and interferon- a in advanced cutaneous T-cell lymphoma Lancet 350 1997 32 33
2. R Edelson C Berger F Gasparro Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy N Engl J Med 316 1987 297 303
3. HK Koh BE Davis T Meola Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T-cell lymphoma (CTCL) J Invest Dermatol 102 1994 567
4. M Duvic J Heaster N Lemak Photopheresis therapy for cutaneous T-cell lymphoma J Am Acad Dermatol 35 1996 573 579